-
Media Release
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
-
Media Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Media Release
NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"
-
Media Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Media Release
Novartis and US government reach agreement on lowering drug prices in the US
-
Media Release
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
-
Media Release
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
-
Media Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Media Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
-
Media Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases